Literature DB >> 2877275

Role of plasma exudation in asthmatic airways.

C G Persson.   

Abstract

In normal airway defence and especially in asthma, mediators released from inflammatory cells will directly affect the walls of the abundant airway microvessels, making them much more permeable to macromolecules. Through large gaps between actively separated (contracted?) endothelial cells of venules of the tracheobronchial circulation, there is a bulk flow of proteinaceous plasma. The plasma exudate is distributed in the airway wall and it readily passes across an inflamed mucosa into the airway lumen. Plasma in the airway wall causes oedema, which may result in hyperresponsiveness and epithelial shedding. In the lumen its effects are formation of mucus plugs and inhibition of mucociliary transport, and its potent mediators such as the protein products of the kinin, complement, and clotting systems are released. Thus plasma exudation may operate in several aspects of asthmatic diathesis. By positive feedback mechanisms and recruitment and conditioning of inflammatory cells plasma exudate may amplify the inflammatory process.

Entities:  

Mesh:

Year:  1986        PMID: 2877275     DOI: 10.1016/s0140-6736(86)90533-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  37 in total

1.  Bradykinin-induced plasma exudation in guinea-pig airways: involvement of platelet activating factor.

Authors:  D F Rogers; S Dijk; P J Barnes
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

2.  Reversibility and reproducibility of histamine induced plasma leakage in nasal airways.

Authors:  C Svensson; C R Baumgarten; U Pipkorn; U Alkner; C G Persson
Journal:  Thorax       Date:  1989-01       Impact factor: 9.139

3.  Quantitative assessment of increased airway microvascular permeability to 125I-labelled plasma fibrinogen induced by platelet activating factor and bradykinin.

Authors:  K E Pedersen; P J Rigby; R G Goldie
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

4.  Neutrophil airway inflammation in childhood asthma.

Authors:  C M McDougall; P J Helms
Journal:  Thorax       Date:  2006-09       Impact factor: 9.139

5.  Lactoferrin and secretory IgA in the bronchoalveolar lavage fluid from patients with a stable asthma.

Authors:  E A van de Graaf; T A Out; A Kobesen; H M Jansen
Journal:  Lung       Date:  1991       Impact factor: 2.584

6.  In vitro modulation of the eosinophil-dependent enhancement of the permeability of the bronchial mucosa.

Authors:  C A Herbert; D Edwards; J R Boot; C Robinson
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

Review 7.  Measurement of airway hyperresponsiveness: new considerations.

Authors:  J Lötvall; M Inman; P O'Byrne
Journal:  Thorax       Date:  1998-05       Impact factor: 9.139

Review 8.  Treatment of childhood asthma. Options and rationale for inhaled therapy.

Authors:  C V Powell; M L Everard
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

9.  Apelin attenuates UVB-induced edema and inflammation by promoting vessel function.

Authors:  Mika Sawane; Hiroyasu Kidoya; Fumitaka Muramatsu; Nobuyuki Takakura; Kentaro Kajiya
Journal:  Am J Pathol       Date:  2011-10-06       Impact factor: 4.307

10.  Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skin.

Authors:  C J Whelan; M Johnson
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.